Compare GBIO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBIO | GSIW |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 33.9M |
| IPO Year | 2020 | 2023 |
| Metric | GBIO | GSIW |
|---|---|---|
| Price | $5.11 | $0.15 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | 75.9K | ★ 1.4M |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,270,000.00 | $5,368,221.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 283.23 |
| 52 Week Low | $3.00 | $0.09 |
| 52 Week High | $15.30 | $1.79 |
| Indicator | GBIO | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 47.18 |
| Support Level | $5.14 | $0.14 |
| Resistance Level | $5.38 | $0.16 |
| Average True Range (ATR) | 0.26 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 18.36 | 41.13 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.